Mark Lappe insider trades: Inhibrx Biosciences (INBX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
43 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | INBX | ↑ Buy | 5,040 | $84.56 | $426K | By the Lappe Family Trust | Oct 14, 2026 (0d) |
| Oct 14, 2026 | INBX | ↑ Buy | 5,000 | $84.56 | $423K | By Lappe Descendants' Trust | Oct 14, 2026 (0d) |
| Sep 28, 2026 | INBX | ↑ Buy | 10,000 | $99.88 | $999K | By the Lappe Family Trust | Sep 28, 2026 (0d) |
| Sep 8, 2026 | INBX | ↑ Buy | 25,000 | $105.82 | $2.6M | By the Lappe Family Trust | Sep 8, 2026 (0d) |
| Sep 16, 2024 | INBX | ↑ Buy | 40,000 | $15.73 | $629K | By the Lappe Family Trust | Sep 16, 2024 (0d) |
| Sep 10, 2024 | INBX | ↑ Buy | 44,000 | $15.25 | $671K | By the Lappe Family Trust | Sep 10, 2024 (0d) |
| Sep 3, 2024 | INBX | ↑ Buy | 40,000 | $14.92 | $597K | By Lappe Descendants' Trust | Sep 3, 2024 (0d) |
| Aug 21, 2024 | INBX | ↑ Buy | 40,000 | $12.96 | $518K | The Mark Paul Lappe Roth IRA | Aug 22, 2024 (1d) |
| Feb 28, 2023 | INBX | ↓ Sell | 60 | $25.02 | $2K | By the Lappe Family Trust | Mar 1, 2023 (1d) |
| Jan 24, 2023 | INBX | ↓ Sell | 26,000 | $25.42 | $661K | By the Lappe Family Trust | Jan 24, 2023 (0d) |
| Dec 19, 2022 | INBX | ↓ Sell | 26,000 | $25.56 | $664K | By the Lappe Family Trust | Dec 20, 2022 (1d) |
| Nov 17, 2022 | INBX | ↓ Sell | 26,000 | $27.88 | $725K | By the Lappe Family Trust | Nov 18, 2022 (1d) |
| Oct 17, 2022 | INBX | ↓ Sell | 26,000 | $29.59 | $769K | By the Lappe Family Trust | Oct 18, 2022 (1d) |
| Mar 16, 2011 | AOLS | ↓ Sell | 3,992,614 | $0.62 | $2.5M | Indirect | Mar 17, 2011 (1d) |
| Feb 16, 2011 | AOLS | ↓ Sell | 64,600 | $0.97 | $63K | Indirect | Feb 17, 2011 (1d) |
| Dec 21, 2009 | RPRX | ↓ Sell | 156,803 | $0.67 | $106K | Indirect | Dec 21, 2009 (0d) |
| Dec 15, 2009 | RPRX | ↓ Sell | 386,100 | $0.68 | $264K | Indirect | Dec 15, 2009 (0d) |
| Dec 2, 2009 | RPRX | ↓ Sell | 541,000 | $0.70 | $381K | Indirect | Dec 2, 2009 (0d) |
| Nov 23, 2009 | RPRX | ↓ Sell | 656,000 | $0.72 | $471K | Indirect | Nov 23, 2009 (0d) |
| Oct 31, 2008 | RPRX | ↑ Buy | 11,300 | $7.76 | $88K | Efficacy Capital | Nov 4, 2008 (4d) |
| Oct 31, 2008 | RPRX | ↑ Buy | 11,300 | $7.76 | $88K | Indirect | Nov 4, 2008 (4d) |
| Oct 29, 2008 | RPRX | ↑ Buy | 34,292 | $6.94 | $238K | Indirect | Oct 30, 2008 (1d) |
| Oct 29, 2008 | RPRX | ↑ Buy | 34,292 | $6.94 | $238K | Efficacy Capital | Oct 30, 2008 (1d) |
| Oct 27, 2008 | RPRX | ↑ Buy | 62,134 | $6.72 | $418K | Efficacy Capital | Oct 27, 2008 (0d) |
| Oct 27, 2008 | RPRX | ↑ Buy | 62,134 | $6.72 | $418K | Indirect | Oct 27, 2008 (0d) |
| Oct 17, 2008 | RPRX | ↑ Buy | 30,000 | $6.42 | $193K | Efficacy Capital | Oct 21, 2008 (4d) |
| Oct 17, 2008 | RPRX | ↑ Buy | 30,000 | $6.42 | $193K | Indirect | Oct 21, 2008 (4d) |
| Oct 13, 2008 | RPRX | ↑ Buy | 30,300 | $6.52 | $198K | Indirect | Oct 14, 2008 (1d) |
| Oct 13, 2008 | RPRX | ↑ Buy | 30,300 | $6.52 | $198K | Through ownership by Efficacy Capital | Oct 14, 2008 (1d) |
| Oct 2, 2008 | RPRX | ↑ Buy | 1,846,154 | $6.50 | $12.0M | Indirect | Oct 6, 2008 (4d) |
| Oct 2, 2008 | RPRX | ↑ Buy | 1,846,154 | $6.50 | $12.0M | Through ownership by Efficacy Capital | Oct 6, 2008 (4d) |
| Mar 27, 2008 | RPRX | ↓ Sell | 302,057 | $9.21 | $2.8M | Indirect | Jul 3, 2008 (98d) |
| Mar 12, 2008 | RPRX | ↑ Buy | 50,000 | $8.50 | $425K | By investment funds | Mar 13, 2008 (1d) |
| Mar 10, 2008 | RPRX | ↑ Buy | 74,500 | $8.54 | $636K | By investment funds | Mar 11, 2008 (1d) |
| Feb 29, 2008 | RPRX | ↑ Buy | 50,000 | $8.30 | $415K | By investment funds | Mar 3, 2008 (3d) |
| Jan 7, 2008 | RPRX | ↑ Buy | 34,500 | $9.03 | $311K | By investment funds | Jan 8, 2008 (1d) |
| Dec 31, 2007 | RPRX | ↑ Buy | 124,100 | $9.37 | $1.2M | By Investment funds | Jan 2, 2008 (2d) |
| Dec 21, 2007 | RPRX | ↑ Buy | 100,000 | $9.45 | $945K | By investment funds | Dec 21, 2007 (0d) |
| Dec 19, 2007 | RPRX | ↑ Buy | 85,600 | $9.82 | $840K | By investment funds | Dec 20, 2007 (1d) |
| Dec 14, 2007 | RPRX | ↑ Buy | 160,100 | $9.51 | $1.5M | By investment funds | Dec 18, 2007 (4d) |
| Dec 6, 2007 | RPRX | ↑ Buy | 99,300 | $8.05 | $799K | By investment funds | Dec 7, 2007 (1d) |
| Dec 4, 2007 | RPRX | ↑ Buy | 121,500 | $8.06 | $979K | By investment funds | Dec 5, 2007 (1d) |
| Oct 25, 2007 | RPRX | ↑ Buy | 217,000 | $12.44 | $2.7M | By investment funds | Nov 2, 2007 (8d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other INBX insiders
Open-market trades in the last 12 months
About Mark Lappe's insider trades
Mark Lappe is Chief Executive Officer at Inhibrx Biosciences (INBX). Since Oct 25, 2007, Mark has reported 31 open-market purchases worth $43.9M and 12 sales worth $9.4M on SEC Form 4. In the last 12 months: 4 buys ($4.5M).
Their filings also include grants and awards (5 filings), other transactions (2 filings), shares returned to the company (1 filing), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INBX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.